Targets › NOTCH1
2 programs from 2 companies in 2 trials: 1 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.
Functions as a receptor for membrane-bound ligands Jagged-1 (JAG1), Jagged-2 (JAG2) and Delta-1 (DLL1) to regulate cell-fate determination. Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus. (UniProt, P46531)
Open in Phaseline: the race on NOTCH1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Immunome | AL102 Gamma secretase inhibitor targeting Notch signaling | NOTCH1, NOTCH2, NOTCH3 | Phase 2 | Desmoid | Dec 2026 |
| Michael J. Dennis, MD | CB-103 Pan-NOTCH pathway inhibitor | NOTCH1, NOTCH2, NOTCH3, NOTCH4 | Phase 1 | Adenoid Cystic Carcinoma | Jun 2027 |
Adenoid Cystic Carcinoma (1) Desmoid (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.